NorthWest Biotherapeutics Inc (NWBO)

[Doc logic]

exwannabe,

At crossover (after progression) about 85% of tumors became mesenchymal signature based on historical numbers attributed to transition into more aggressive mesenchymal phenotype. By the time original treatment patients progressed, most or all of their vaccines were likely used up leaving very little to no additional benefit from crossover. This means original treatment patients had about 50% mesenchyma,l more of which would have been unmethylated status, and crossovers had about 85% mesenchymal with likely more methylated status percentage wise vs original treatment arm carried through from original association to tumor genotype. However, moving past the medians we see that original treatment had a higher percentage of long livers which is the ultimate advantage being strived for. So the discrepancy you point out does not take into account the advantage of a higher long liver status being imparted by early treatment vs late, the higher rate of mesenchymal at transition able to benefit from active vaccines or the higher % rate of methylation in the crossover population. JAMA Oncology editors and reviewers would have been very aware. Go fish!; ). Best wishes.